Canagliflozin/metformin
{{Short description|Fixed-dose combination anti-diabetic medication}}
{{Use dmy dates|date=March 2020}}
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{Infobox drug
| type = combo
| image =
| width =
| alt =
| caption =
| component1 = Canagliflozin
| class1 = SGLT2 inhibitor
| component2 = Metformin
| class2 = Biguanide
| tradename = Vokanamet, Invokamet
| Drugs.com = {{drugs.com|monograph|canagliflozin}}
| MedlinePlus =
| DailyMedID = Invokamet
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration = By mouth
| ATC_prefix = A10
| ATC_suffix = BD16
| ATC_supplemental =
| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA = Rx-only
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK = POM
| legal_US = Rx-only
| legal_EU = Rx-only
| legal_UN =
| legal_UN_comment =
| legal_status = Rx-only
| CAS_number = 2131792-63-5
| CAS_supplemental =
| PubChem =
| IUPHAR_ligand =
| DrugBank =
| ChemSpiderID =
| UNII =
| KEGG = D10587
| ChEBI =
| ChEMBL =
| NIAID_ChemDB =
| PDB_ligand =
| synonyms =
}}
Canagliflozin/metformin, sold under the brand name Vokanamet among others, is a fixed-dose combination anti-diabetic medication used for the treatment of type 2 diabetes.{{cite web | title=Invokamet- canagliflozin and metformin hydrochloride tablet, film coated Invokamet XR- canagliflozin and metformin hydrochloride tablet, film coated, extended release | website=DailyMed | date=5 February 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6868666b-c25e-40d1-9d1f-306bbe9390c1 | access-date=2 March 2020 | archive-date=7 June 2020 | archive-url=https://web.archive.org/web/20200607021228/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6868666b-c25e-40d1-9d1f-306bbe9390c1 | url-status=live }} It is used in combination with diet and exercise. It is taken by mouth.
The most common side effects include hypoglycemia (low blood glucose levels) when used in combination with insulin or a sulphonylurea and vulvovaginal candidiasis (thrush, a fungal infection of the female genital area caused by Candida).
Canagliflozin/metformin was approved for medical use in the European Union in April 2014,{{cite web | title=Vokanamet EPAR | website=European Medicines Agency (EMA) | date=18 February 2020 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/vokanamet | access-date=2 March 2020 | archive-date=3 March 2020 | archive-url=https://web.archive.org/web/20200303084159/https://www.ema.europa.eu/en/medicines/human/EPAR/vokanamet | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. and for use in the United States in August 2014.{{cite web | title=Drug Approval Package: Invokamet (canagliflozin and metformin hydrochloride) Tablets NDA #204353 | website=U.S. Food and Drug Administration (FDA) | date=4 September 2014 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204353Orig1s000TOC.cfm | access-date=2 March 2020 | archive-date=3 March 2020 | archive-url=https://web.archive.org/web/20200303084147/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204353Orig1s000TOC.cfm | url-status=live }}
Medical uses
Canagliflozin/metformin is indicated in adults aged 18 years of age and older with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control.
Adverse effects
{{See also|Canagliflozin#Adverse_effects|Metformin#Adverse_effects}}
To lessen the risk of developing ketoacidosis (a serious condition in which the body produces high levels of blood acids called ketones) after surgery, the FDA approved changes to the prescribing information for SGLT2 inhibitor diabetes medicines to recommend they be stopped temporarily before scheduled surgery. Canagliflozin, dapagliflozin, and empagliflozin should each be stopped at least three days before, and ertugliflozin should be stopped at least four days before scheduled surgery.{{cite web | title=FDA revises labels of SGLT2 inhibitors for diabetes to include warning | website=U.S. Food and Drug Administration (FDA) | date=19 March 2020 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious | access-date=6 June 2020 | archive-date=7 June 2020 | archive-url=https://web.archive.org/web/20200607011955/https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious | url-status=live }} {{PD-notice}}
Symptoms of ketoacidosis include nausea, vomiting, abdominal pain, tiredness, and trouble breathing.
References
{{reflist}}
Further reading
- {{cite journal |vauthors=Davidson JA, Sloan L |title=Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview |journal=Adv Ther |volume=34 |issue=1 |pages=41–59 |date=January 2017 |pmid=27854055 |pmc=5216068 |doi=10.1007/s12325-016-0434-2 }}
{{Oral hypoglycemics and insulin analogs}}
{{Sodium-glucose transporter modulators}}
{{Portal bar | Medicine}}
{{Authority control}}
{{DEFAULTSORT:Canagliflozin Metformin}}